Trip.com, Boston Scientific, Lyft, WES, Magna Trending With Analysts - TipRanks.com

An analyst downgraded Lyft (LYFT) stock, though the consensus rating remains 'Moderate Buy' with a mean price target of $19.83, suggesting 30% upside from current levels.

Citi downgraded Boston Scientific (BSX) to neutral, citing uncertainty from a recent cyberattack and competitive pressures. The firm lowered its target price to $50 and expects declines in Watchman and Farapulse sales. BSX shares have fallen 13% in a month, underperforming the S&P 500.

Boston Scientific (BSX) is launching a multicenter trial to evaluate the safety and effectiveness of its Eso-SPONGE device for treating upper GI leaks. The trial aims to assess the device's ability to close leak sites post-surgery, offering a less invasive alternative. The study is not yet recruiting, with updates indicating active planning. Positive results could support BSX's pipeline in minimally invasive GI solutions and potentially impact competitors.

Magna International (MGA) shares fell 3.1% after BMO Capital downgraded the stock from Outperform to Market Perform, lowering the price target from $76 to $70. The stock traded at CA$87.93, down from its day high of CA$89.59. No corporate announcements were made, and broader market declines contributed to the drop. The analyst cited a less compelling risk-reward balance at current levels.

BMO Capital downgraded Magna International (MGA) to Market Perform, lowering its price target from $76 to $70. The stock is currently trading at $64.82, which is 32.6% above its GF Value™ of $48.90. Magna has a GF Score™ of 79/100, indicating strong overall performance but with concerns about valuation.

Boston Scientific shares declined after Citigroup downgraded the stock to 'Neutral' from 'Buy' and lowered its price target to $50 from $57. The company's shares are currently trading at $43.20, down 1.62% on the day but up 0.61% year-to-date, according to Citigroup.